Report
- +2
George Perkovich, Jessica Tuchman Mathews, Joseph Cirincione, …
{
"authors": [
"Jon Wolfsthal"
],
"type": "other",
"centerAffiliationAll": "dc",
"centers": [
"Carnegie Endowment for International Peace"
],
"collections": [
"Korean Peninsula"
],
"englishNewsletterAll": "ctw",
"nonEnglishNewsletterAll": "",
"primaryCenter": "Carnegie Endowment for International Peace",
"programAffiliation": "NPP",
"programs": [
"Nuclear Policy"
],
"projects": [],
"regions": [
"East Asia",
"North Korea"
],
"topics": [
"Nuclear Policy"
]
}
Source: Getty
Other
Our Missile Defenses Go to 11
Despite spending tens of billions of dollars on missile defense over the last 30 years, the United States remains unable to shoot down North Korean ICBMs.
Published on Nov 14, 2017
Source: Foreign Policy
I usually write longer, detailed essays for this column but today’s submission is simpler. And it has a simple message. Missile defense will not protect the United States from North Korean missiles. I know a lot of people think the opposite is true. Even President Donald Trump has asserted we have a 97 percent chance of shooting down a North Korean intercontinental ballistic missile (ICBM). But, as they say, “um, no.”
It would make sense for you to scratch your head and ask how can we have spent tens of billions of dollars over 30 years and still not be able to shoot down a couple of North Korea missiles. But, sorry, we can’t.
This is true for a whole host of reasons, but let’s get right to the chase. Our missile defenses don’t work all that well (better than they used to, but far from reliable and very far from perfect) and we don’t have very many of them. It is like the old joke about the married couple. The wife complains “the food at this restaurant is terrible!” To which her husband responds: “Yeah, and the portions are small, too.”
Current U.S. military planning would shoot four ground-based interceptors (GBIs) in Alaska or California at each incoming North Korean ICBM. Do the math. We shoot four at each incoming missile because each interceptor has about a 25 percent chance of working: i.e. hitting its target. And that assumes everything goes right. So far, however, little goes right for our GBIs and none have ever taken down an ICBM in a realistic, real-time, no-notice test. In fact, the reason the United States purchased so few GBIs in the Obama years is because the ones we had already purchased did not work all that well. Time and money were needed to fix major systemic problems. They’re better now, but still far from perfect.
This article was originally published in Foreign Policy
Read the article
About the Author
Jon Wolfsthal
Former Nonresident Scholar, Nuclear Policy Program
Jon Wolfsthal was a nonresident scholar with the Nuclear Policy Program.
- Universal Compliance: A Strategy for Nuclear Security<br>With 2007 Report Card on Progress
- 10 Plus 10 Doesn’t Add UpArticle
Jon Wolfsthal
Recent Work
Carnegie does not take institutional positions on public policy issues; the views represented herein are those of the author(s) and do not necessarily reflect the views of Carnegie, its staff, or its trustees.
More Work from Carnegie Endowment for International Peace
- The Fallout of the U.S.–Canada Trade War Won’t Be Limited to North AmericaCommentary
U.S. trading partners in Asia are closely watching the dispute for signs of how it may affect their own interests.
Barbara Weisel
- Is the U.S.-Saudi Nuclear Deal Moving From the Gold Standard to a Gilded Standard?Commentary
Congress should ask tough questions about the agreement’s more unique features and whether they advance U.S. interests or compromise them.
Jane Darby Menton
- A Nuclear Odyssey at SeaCommentary
Nuclear and maritime communities face a long and challenging journey to deploy commercial nuclear applications at sea.
Jamie Kwong, Toby Dalton
- The Two Logics Driving Japan’s Security PolicyArticle
Japan’s revision of its three strategic documents reflects an intention to keep the United States engaged in the region while Japan fills any vacuums of U.S. power to preserve the Indo-Pacific order.
Ryo Sahashi
- Caught in the Middle: Chinese Biotech Firms’ Divergent Responses to U.S. SanctionsCommentary
Chinese biotech companies have been on the receiving end of U.S. economic coercion. Yet their responses have differed significantly because firm and state interests are not uniformly aligned. For Washington, treating all Chinese tech firms the same, irrespective of their actual interests, risks pushing them farther into Beijing’s corner.
Xue Gong
